Glomerular Hyperfiltration and Renal Progression in Children with Autosomal Dominant Polycystic Kidney Disease

被引:62
|
作者
Helal, Imed [1 ]
Reed, Berenice [1 ]
McFann, Kim [1 ]
Yan, Xiang-Dong [1 ]
Fick-Brosnahan, Godela M. [1 ]
Cadnapaphornchai, Melissa [1 ]
Schrier, Robert W. [1 ]
机构
[1] Univ Colorado Denver, Div Renal Dis & Hypertens, Aurora, CO 80045 USA
来源
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY | 2011年 / 6卷 / 10期
关键词
VOLUME PROGRESSION; ADPKD; DIAGNOSIS; RISK; MICROALBUMINURIA; CREATININE; GROWTH; END;
D O I
10.2215/CJN.01010211
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background and objectives The purpose of this study was to determine whether glomerular hyperfiltration (GH) occurring early in autosomal dominant polycystic kidney disease (ADPKD) is indicative of more rapid disease progression in children. Design, setting, participants, & measurements One hundred eighty children with ADPKD (ages 4 to 18 years) with normal renal function were examined by renal ultrasound. Renal volume was calculated using a standard formula for a modified ellipsoid. Creatinine clearance was calculated from serum creatinine and 24-hour urine creatinine. GH was defined as creatinine clearance >= 140 ml/min per 1.73 m(2). Results Thirty-two children had GH (mean age 11.4 +/- 3.6 years) and 148 had normal renal function (mean age 10.8 +/- 3.9 years). Patients with GH at baseline demonstrated an increased rate of total renal volume growth (beta: rate of change = +19.3 +/- 10.8 cm(3)/year) over 5 years compared with those without GH at baseline (beta = -4.3 +/- 7.7 cm(3)/year), P = 0.008. Those with GH at baseline experienced a faster decline in creatinine clearance in subsequent years (beta = 5.0 +/- 0.8 ml/min per 1.73 m(2) per year) compared with those without GH at baseline (beta = +1.0 +/- 0.4 ml/min per 1.73 m(2) per year), P < 0.0001. Conclusions This study revealed that occurrence of CH in ADPKD children is associated with a significantly faster decline in renal function and higher rate of kidney enlargement over time. GH combined with the increased renal volume may therefore be used as an early marker for a more severe progression of ADPKD in children. J Am Soc Nephrol 6: 2439-2443, 2011. doi: 10.2215/CJN.01010211
引用
收藏
页码:2439 / 2443
页数:5
相关论文
共 50 条
  • [21] Hypomagnesaemia is absent in children with autosomal dominant polycystic kidney disease
    Seeman, Tomas
    Fortova, Magdalena
    Sopko, Bruno
    Prusa, Richard
    Pohl, Michael
    John, Ulrike
    ANNALS OF CLINICAL BIOCHEMISTRY, 2019, 56 (01) : 90 - 94
  • [22] Autosomal Dominant Polycystic Kidney Disease
    Srivastava, Ajay
    Patel, Neel
    AMERICAN FAMILY PHYSICIAN, 2014, 90 (05) : 303 - 307
  • [23] Hypertension in Children with Autosomal Dominant Polycystic Kidney Disease (ADPKD)
    Cadnapaphornchai, Melissa A.
    CURRENT HYPERTENSION REVIEWS, 2013, 9 (01) : 21 - 26
  • [24] The spectrum of autosomal dominant polycystic kidney disease in children and adolescents
    Bharathi V. Reddy
    Arlene B. Chapman
    Pediatric Nephrology, 2017, 32 : 31 - 42
  • [25] cGAS Activation Accelerates the Progression of Autosomal Dominant Polycystic Kidney Disease
    Yoo, Miran
    Haydak, Jonathan C.
    Azeloglu, Evren U.
    Lee, Kyung
    Gusella, G. Luca
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2024, 35 (04): : 466 - 482
  • [26] Autosomal Dominant Polycystic Kidney Disease
    Perumareddi, Parvathi
    Trelka, Darin P.
    PRIMARY CARE, 2020, 47 (04): : 673 - 689
  • [27] Autosomal Dominant Polycystic Kidney Disease
    Suarez, Maria Lourdes Gonzalez
    Titan, Silvia
    Dahl, Neera K.
    ADVANCES IN KIDNEY DISEASE AND HEALTH, 2024, 31 (06): : 496 - 503
  • [28] Autosomal dominant polycystic kidney disease
    Cornec-Le Gall, Emilie
    Alam, Ahsan
    Perrone, Ronald D.
    LANCET, 2019, 393 (10174) : 919 - 935
  • [29] The spectrum of autosomal dominant polycystic kidney disease in children and adolescents
    Reddy, Bharathi V.
    Chapman, Arlene B.
    PEDIATRIC NEPHROLOGY, 2017, 32 (01) : 31 - 42
  • [30] Association of plasma somatostatin with disease severity and progression in patients with autosomal dominant polycystic kidney disease
    Messchendorp, A. Lianne
    Spithoven, Edwin M.
    Casteleijn, Niek F.
    Dam, Wendy A.
    van den Born, Jacob
    Tonnis, Wouter F.
    Gaillard, Carlo A. J. M.
    Meijer, Esther
    Drenth, Joost
    de Fijter, Johan W.
    Gansevoort, Ron T.
    Peters, Dorien J. M.
    Wetzels, Jack F. M.
    Zietse, Robert
    BMC NEPHROLOGY, 2018, 19